This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / AbbVie Awards RIME Therapeutics in Quebec
Business award grant

AbbVie Awards RIME Therapeutics in Quebec

Analysis based on 7 articles · First reported Apr 30, 2026 · Last updated Apr 30, 2026

Sentiment
40
Attention
2
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The award to Rime Therapeutics, funded by AbbVie and supported by AdMare BioInnovations, is expected to accelerate drug discovery in inflammation and immunology, potentially leading to new therapies. This collaboration highlights a positive trend in the biotechnology sector, where established companies support early-stage innovators, fostering growth and innovation within the life sciences market, particularly in Canada — Quebec and Canada.

Biotechnology Pharmaceuticals
Event Summary

AbbVie, in collaboration with AdMare BioInnovations, has recognized Rime Therapeutics as the recipient of the AbbVie Biotech Innovators Award. This award provides Rime Therapeutics with a year of laboratory and office space, access to shared equipment and services at the AdMare Innovation Centre in Montreal, and mentorship from AbbVie's scientific and business leaders. Rime Therapeutics, founded in 2025, is a Montreal-based start-up focused on developing a peptide-based drug discovery platform for inflammation and immunology therapies. The award aims to foster innovation and support growth in Canada — Quebec's life sciences sector, aligning with AbbVie's therapeutic areas of focus including immunology, oncology, neuroscience, and aesthetics. Michael Mee, CEO of Rime Therapeutics, and Matthew Carlyle, President and CEO of AdMare BioInnovations, both expressed enthusiasm for the partnership and its potential to advance Canadian life sciences.

Entities Involved
priv
Rime Therapeutics
Rime Therapeutics is the recipient of the AbbVie Biotech Innovators Award, which provides it with a year of laboratory and office space, access to shared equipment, and mentorship from AbbVie's scientific and business leaders, accelerating its drug discovery efforts in inflammation and immunology.
Importance 100.0 Sentiment 60.0
priv
AdMare BioInnovations
AdMare BioInnovations, Canada's life sciences company creation engine, co-sponsored the award and will provide Rime Therapeutics with laboratory and office space, equipment, and mentorship, aligning with its mission to build and scale competitive Canadian life sciences companies.
Importance 80.0 Sentiment 20.0
per
Michael Mee
Michael Mee, CEO of Rime Therapeutics, expressed honor in receiving the award, highlighting its support for Rime Therapeutics' Disruptide Platform and its goal to accelerate the path from novel biology to tractable chemistry.
Importance 50.0 Sentiment 20.0
per
Matthew Carlyle
Matthew Carlyle, President and CEO of AdMare BioInnovations, stated that the award reflects AdMare BioInnovations' focus on creating and scaling globally competitive Canadian life sciences companies.
Importance 40.0 Sentiment 10.0
per
Stephanie Sauvageau
Stephanie Sauvageau, Head of Medical at AbbVie Canada, emphasized AbbVie's commitment to fostering a thriving life sciences ecosystem in Canada — Quebec and Canada through the award.
Importance 40.0 Sentiment 10.0
stock
AbbVie
Importance 0.0 Sentiment 0.0
loc
Canada — Quebec
Importance 0.0 Sentiment 0.0
cnt
Canada
Importance 0.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.